Get the Stockscreener App
4.90
1.80%
-0.09
After Hours:
4.90
Iovance Biotherapeutics Inc stock is traded at $4.90, with a volume of 13.21M.
It is down -1.80% in the last 24 hours and up +15.29% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$4.99
Open:
$5.02
24h Volume:
13.21M
Relative Volume:
0.86
Market Cap:
$2.19B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-5.1574
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
-2.39%
1M Performance:
+15.29%
6M Performance:
+64.43%
1Y Performance:
+56.55%
1-Day Range:
$4.855
$5.16
1-Week Range:
$4.855
$5.64
52-Week Range:
$1.76
$5.64
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.90 | 2.23B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IOVA|Iovance Biotherapeutics Inc|Price:4.990|Chg%:-0.140 - TradingKey
Iovance Biotherapeutics Inc (IOVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Iovance Biotherapeutics Inc Revenue Breakdown – BX:IOVA - TradingView
TradingKey - TradingKey
Iovance Biotherapeutics Inc Revenue Breakdown – MIL:1IOVA - TradingView
Iovance Shares Close Unchanged After Choppy Trading; 2026 Sales Target Puts Pressure on Growth Pace - TechStock²
Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance Biotherapeutics (IOVA) Rallies On Undervalued Claims, Is The Market Still Missing Fair Value? - Sahm
Iovance Biotherapeutics Market Sentiment - Benzinga España
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 71.54% Potential Upside in Biotech - DirectorsTalk Interviews
Iovance Biotherapeutics Inc (IOVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada
Iovance Biotherapeutics stock hits 52-week high at $5.64 By Investing.com - Investing.com South Africa
Iovance Biotherapeutics stock hits 52-week high at $5.64 - Investing.com
Iovance Biotherapeutics (IOVA) Stock Looks Fully Priced Despite Strong 117% Returns - Sahm
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Why Is IOVA Stock Falling Today? - Stocktwits
Iovance (NASDAQ:IOVA) advances 18% in a week, drawing attention to Amtagvi sales goals - TechStock²
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches - TechStock²
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Gives 17 New Employees Options That Vest Over 3 Years - Stock Titan
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance shares surge as attention shifts to Amtagvi’s second-half sales target - TechStock²
$4.659 | Iovance Biotherapeutics, Inc. Common Stock (IOVA) Stock Price Today - Binance
ETFs Investing in Iovance Biotherapeutics Inc Stocks - TradingView
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy) (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value - TechStock²
IOVA Stock Holds Range As Capital Plans And Hiring Ramp Up - StocksToTrade
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IOVA Stock Price, Quote & Chart - ChartMill
Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative - Sahm
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note - Insider Monkey
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
This Stock Is Up 74% This Year: Is It Too Late to Buy? - The Motley Fool
Enterprise value to revenue forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):